A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Our Company We were incorporated in Delaware on January 13, 2009. We manufacture high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. We specialize in custom gels by capitalizing on proprietary manufacturing technologies. We have historically served as a contract manufacturer, supplying our gels to third parties who incorporate them into their own products. Beginning in 2020, we created two new lines of business for the company. First, our own line of branded consumer products sold direct to consumers. Second, we expanded into custom and white label opportunities, which focuses on combining our gels with proprietary branded products and white label opportunities. All of our gel products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 12M | 8.7M | 4.1M | - | - | - |
| Net Income | -2.9M | -3.3M | -3.2M | -4.7M | -4.3M | -2.3M |
| EPS | $-0.37 | $-0.50 | $-0.56 | $-0.85 | $-1.45 | $-1.05 |
| Free Cash Flow | 0 | -4.3M | -3.9M | -3.1M | -3.0M | -2.1M |
| ROIC | -63.1% | -54.1% | -60.6% | -59.9% | -35.3% | -394.1% |
| Gross Margin | 38.3% | 31.6% | 9.1% | - | - | - |
| Debt/Equity | 0.08 | 0.08 | 0.14 | 0.04 | 0.18 | 5.83 |
| Dividends/Share | $0.00 | $0.00 | $0.00 | $0.00 | - | - |
| Operating Income | -3.0M | -3.6M | -3.5M | -3.3M | -2.6M | -2.3M |
| Operating Margin | -25.5% | -40.9% | -85.0% | - | - | - |
| ROE | -55.5% | -62.8% | -67.2% | -48.1% | -70.9% | -1004.0% |
| Shares Outstanding | 8M | 7M | 6M | 6M | 3M | 2M |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | |||
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 2.2M | N/A | N/A | N/A | N/A | 4.1M | 8.7M | 12M |
| Gross Margin | 23.2% | N/A | N/A | N/A | N/A | 9.1% | 31.6% | 38.3% |
| R&D | N/A | N/A | N/A | 31K | 367K | 103K | 78K | 8K |
| SG&A | 2.4M | 1.8M | 2.0M | 2.5M | 3.2M | 3.7M | 6.2M | 7.4M |
| EBIT | -1.9M | -1.9M | -2.3M | -2.6M | -3.3M | -3.5M | -3.6M | -3.0M |
| Op. Margin | -85.3% | N/A | N/A | N/A | N/A | -85.0% | -40.9% | -25.5% |
| Net Income | -1.9M | -1.9M | -2.3M | -4.3M | -4.7M | -3.2M | -3.3M | -2.9M |
| Net Margin | -85.3% | N/A | N/A | N/A | N/A | -77.2% | -37.8% | -24.7% |
| Non-Recurring | 5K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||||
| ROIC | N/M | N/M | N/M | -35.3% | -59.9% | -60.6% | -54.1% | -63.1% |
| ROE | -416.8% | -581.8% | -1004.0% | -70.9% | -48.1% | -67.2% | -62.8% | -55.5% |
| ROA | -255.5% | -146.3% | -109.2% | -44.8% | -34.7% | -31.7% | -31.3% | -24.8% |
| Cash Flow | ||||||||
| Op. Cash Flow | -1.5M | -1.8M | -1.8M | -2.8M | -3.0M | -3.2M | -3.9M | -2.5M |
| Free Cash Flow | -1.5M | -1.8M | -2.1M | -3.0M | -3.1M | -3.9M | -4.3M | 0 |
| Owner Earnings | -1.9M | -1.9M | -2.1M | -3.2M | -3.4M | -3.7M | -4.7M | -3.5M |
| CapEx | 0 | 0 | 312K | 269K | 96K | 696K | 443K | 0 |
| Maint. CapEx | 322K | 67K | 50K | 113K | 112K | 226K | 436K | 446K |
| Growth CapEx | N/A | N/A | 262K | 156K | 0 | 470K | 7K | 0 |
| D&A | 322K | 67K | 50K | 113K | 112K | 226K | 436K | 446K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | 0.0% | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | 0 | 4K | 232K | 285K | 298K | 217K | 367K | 594K |
| Debt Repayment | 0 | 0 | 0 | 100K | 3.5M | 175K | 175K | 175K |
| Balance Sheet | ||||||||
| Net Debt | 0 | -261K | 382K | -11M | 7.0M | -4.7M | -3.2M | -1.5M |
| Cash & Equiv. | 0 | 261K | 32K | 13M | -12M | 2.7M | 1.8M | 1.9M |
| Long-Term Debt | N/A | N/A | N/A | 127K | 283K | 513K | 307K | 259K |
| Debt/Equity | 0.00 | 0.00 | 5.83 | 0.18 | 0.04 | 0.14 | 0.08 | 0.08 |
| Interest Coverage | N/A | N/A | -282.5 | -1.3 | -2.5 | -231.8 | -43.9 | -43.9 |
| Equity | 281K | 380K | 71K | 12M | 7.6M | 4.7M | 5.8M | 5.2M |
| Total Assets | 739K | 1.9M | 2.3M | 17M | 10M | 10.0M | 11M | 12M |
| Total Liabilities | 458K | 1.5M | 2.2M | 4.9M | 2.7M | 4.8M | 4.9M | 6.0M |
| Intangibles | N/A | 0 | 358K | 344K | 331K | 1.5M | 1.9M | 1.8M |
| Retained Earnings | 0 | -238K | -2.5M | -6.8M | -12M | -15M | -18M | -20M |
| Working Capital | -46K | -287K | -969K | 11M | 6.6M | 2.5M | 2.6M | 2.3M |
| Current Assets | 361K | 513K | 363K | 14M | 7.5M | 5.1M | 5.1M | 5.6M |
| Current Liabilities | 407K | 800K | 1.3M | 2.9M | 859K | 2.5M | 2.5M | 3.3M |
| Per Share Data | ||||||||
| EPS | -0.38 | -0.14 | -1.05 | -1.45 | -0.85 | -0.56 | -0.50 | -0.37 |
| Owner EPS | -0.03 | -0.03 | -0.97 | -1.06 | -0.61 | -0.65 | -0.71 | -0.43 |
| Book Value | 0.00 | 0.01 | 0.03 | 4.07 | 1.37 | 0.83 | 0.88 | 0.64 |
| Cash Flow/Share | -0.03 | -0.03 | -0.84 | -0.93 | -0.54 | -0.57 | -0.59 | -0.30 |
| Dividends/Share | N/A | N/A | N/A | N/A | 0.00 | 0.00 | 0.00 | 0.00 |
| Shares Out. | 57.5M | 57.5M | 2.2M | 3.0M | 5.6M | 5.6M | 6.6M | 8.1M |
| Valuation | ||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -1.6 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | 0.7 | N/A | N/A | N/A | 0.9 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.4 |
| FCF Yield | N/A | N/A | N/A | -34.8% | N/A | N/A | N/A | N/A |
| Market Cap | N/A | N/A | N/A | 8.7M | 0 | 0 | 0 | 4.8M |
| Avg. Price | N/A | N/A | N/A | 3.18 | 0.00 | 0.00 | 0.00 | 0.59 |
| Year-End Price | N/A | N/A | N/A | 2.92 | 0.00 | 0.00 | 0.00 | 0.59 |
NEXGEL, INC. passes 0 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 20.4%.
NEXGEL, INC. (NXGL) has a 5-year average return on invested capital (ROIC) of -52.5%. This is below average and may indicate limited pricing power.
NEXGEL, INC. (NXGL) has a market capitalization of $5M. It is classified as a small-cap stock.
NEXGEL, INC. (NXGL) does not currently pay a regular dividend.
NEXGEL, INC. (NXGL) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
NEXGEL, INC. (NXGL) reported annual revenue of $9 million in its most recent fiscal year, based on SEC EDGAR filings.
NEXGEL, INC. (NXGL) has a net profit margin of -37.8%. The company is currently unprofitable.
NEXGEL, INC. (NXGL) generated $-4 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
NEXGEL, INC. (NXGL) has a debt-to-equity ratio of 0.08. This indicates a conservatively financed balance sheet.
NEXGEL, INC. (NXGL) reported earnings per share (EPS) of $-0.50 in its most recent fiscal year.
NEXGEL, INC. (NXGL) has a return on equity (ROE) of -62.8%. A negative ROE may indicate losses or negative equity.
NEXGEL, INC. (NXGL) has a 5-year average gross margin of 20.4%. This lower margin is typical of capital-intensive or commodity businesses.
The Ledger Terminal provides 7 years of financial data for NEXGEL, INC. (NXGL), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
NEXGEL, INC. (NXGL) has a book value per share of $0.88, based on its most recent annual SEC filing.